Biomea Fusion

Biomea Fusion, established in 2017 by a group of biotech executives, focuses on developing advanced therapies for patients. The company utilizes its proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Its lead product candidate, BMF-219, is an orally bioavailable, potent, and selective covalent inhibitor of MENIN, targeting multiple cancers. Additionally, Biomea Fusion is developing BMF-500, a novel, orally bioavailable, highly potent, and selective covalent small molecule inhibitor of fms-like tyrosine kinase 3 (FLT3). The company aims to become a leader in developing covalent small molecules to maximize the depth and durability of clinical benefits in treating various cancers and metabolic diseases. Biomea Fusion has received FDA clearance for Investigational New Drug (IND) applications for its lead compounds and is conducting multiple clinical trials, including COVALENT-111 for Type 2 diabetes and COVALENT-101 for various cancers. The company has raised significant funding through an initial public offering to support its clinical and development programs.